<DOC>
	<DOCNO>NCT01478971</DOCNO>
	<brief_summary>The purpose study understand effect dialysis center switch dialysis patient use Epoetin alfa peginesatide injection hemoglobin level parameter .</brief_summary>
	<brief_title>Conversion Study From Epoetin Alfa Monthly Peginesatide Injection Patients With Chronic Kidney Disease Dialysis</brief_title>
	<detailed_description>Monthly Erythropoiesis-Stimulating Agents ( ESA ) dosing , compare longstanding practice dose three time per week , represent significant change anemia treatment dialysis patient . Because difference process need support monthly dose versus thrice weekly dosing , need prospectively identify evaluate factor dialysis environment center-level transition patient one ESA another . AFX01-18 Phase 3b open-label , single-arm conversion study conduct 5 hemodialysis site United States , enrol Chronic Kidney Disease ( CKD ) patient receive outpatient , in-center hemodialysis . The study treatment period approximately 12 month duration . Participants receive peginesatide injection approximately six month .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Have provide write informed consent accordance institutional , local , national guideline Are ≥18 year age start screen Have incenter hemodialysis ≥12 week start screen Are currently maintain Epoetin start screen If sexually active female childbearing potential , willing use highly effective method birth control ≥4 week study enrollment study If female childbearing potential , negative pregnancy test screening Are schedule renal transplantation study ( Note : patient await transplantation date schedule may enroll . ) Have active malignancy malignancy treat within one year prior start screen curative palliative intent ( Note : patient nonmelanoma skin cancer may enroll . ) Have know intolerance ESA PEGylated molecule Have expose investigational agent four week prior start screen anticipate receive agent study Have significant medical psychiatric condition judge investigator prevent inform consent study compliance Are pregnant nursing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Anemia</keyword>
	<keyword>Chronic Renal Failure</keyword>
	<keyword>CRF</keyword>
	<keyword>Chronic Kidney Disease</keyword>
	<keyword>CKD</keyword>
	<keyword>Erythropoietin</keyword>
	<keyword>Hematide</keyword>
	<keyword>Peginesatide</keyword>
	<keyword>Hemoglobin</keyword>
	<keyword>Hgb</keyword>
	<keyword>Red Blood Cell</keyword>
	<keyword>Red Blood Cell Production</keyword>
	<keyword>Dialysis</keyword>
</DOC>